Comparison of the efficacy of brolucizumab with natural disease progression in wet AMD using clinical data from the Phase III HAWK and HARRIER trials and modelled placebo data
2020
Aim: To compare the treatment effect of brolucizumab, a novel anti-vascular endothelial growth factor therapeutic, with a putative placebo in patients with wet age-related macular degeneration.Mate...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
16
References
2
Citations
NaN
KQI